Disclaimer: Due to limited proficiency, errors are inevitable, and some information may not be the most up-to-date. Feel free to point out in the comments. This article is only an introduction to medical and health-related drugs, not a recommendation of treatment plans (if involved); it does not constitute any investment advice.
According to incomplete statistics, as of August 2025, 11 CGT companies in China have officially announced the completion of financing. Among them, 3 companies focus on cell therapy, 4 concentrate on nucleic acid drug research and development, 2 are committed to novel gene therapies, 1 provides CRO services in the CGT field, and 1 empowers CGT therapies through AI innovation. The following table summarizes these financing events:
Completed A+ Round FinancingOn August 6, 2025, Xiatong Biotech, a cell drug research and development company, officially announced the completion of its A+ round of financing, with the investor being Xia Huitong Technology. This round of financing will fully promote the company's product development and clinical trial progress in the field of iPSC cell therapy for neurodegenerative diseases, bringing more innovative treatment options to patients with nervous system disorders.
The funds from this round of financing will be mainly used to advance the IIT (Investigator-Initiated Trial) and IND (Investigational New Drug Application) for pipelines such as demyelinating diseases.The company is committed to becoming an international pioneer in the application of reprogramming technology in the field of neuroregenerative medicine. Its long-term goal is to transform stem cells into a conventional treatment method, providing innovative therapeutic solutions for tens of millions of patients worldwide suffering from demyelinating diseases. With the completion of this round of financing, Xiatong Biotech will accelerate the advancement of its core pipeline into the clinical stage. Dr. Guo Ying and her team, bearing the mission of "Healthcare Accessibility, Common Well-being," are dedicated to popularizing cell-based therapies in the field of neurological disorders.Nearly 500 Million RMB in Series C FinancingOn August 8, Haichang Biotech announced the completion of a nearly 500 million yuan C-round financing. This round of financing was led by SDIC (Guangdong) Technology Achievement Transformation Venture Capital Fund, with participation from multiple institutions including Jianyuan Shunda (Hangzhou) Equity Investment Fund, Dongguan Songshan Lake Science City Equity Investment Fund, Zhejiang Province's "4+1" Biomedical and High-end Equipment Industry Fund, and Kexing Biopharmaceutical Co., Ltd.
As a national-level specialized and innovative "little giant" enterprise,Haichang Biotech Focuses on the Development and Industrial Application of Drug Delivery Systems`, constructed QTsome with independent intellectual property rights`®and other technical platforms. Haichang Biotech has successfully broken through the international nucleic acid delivery patent barriers, achieving a breakthrough in key "bottleneck" technologies. The innovative small nucleic acid drug HC0301 for primary liver cancer, developed based on the company’s existing technical platforms, has entered Phase II clinical trials in international multicenter studies in China (including Hong Kong, China), the United States, and other regions, becoming one of the fastest progressing pipelines in the global field of precision small nucleic acid tumor treatment. It is the world's first drug based on lipid nanoparticles (QTsome).®) The next-generation TLR9 immunostimulant HC016 lipid complex injection, developed using delivery technology, has received IND approvals in both China and the U.S., entering Phase I clinical trials with Best-in-Class (BIC) potential, showcasing strong innovative capabilities. Meanwhile, the company is developing several potential First-in-Class (FIC) nucleic acid drug pipelines as well as innovative therapies including in vivo cell editing therapies.
In the field of complex injectables, the company's key product, albumin-bound paclitaxel for injection, has been approved for marketing in nearly 40 countries and regions, including China, the EU, the UK, and Peru. The dual production sites of CR Double-Crane Tiantong Pharmaceutical and Kexing Pharmaceutical have simultaneously passed the EU cGMP certification, leading the internationalization process of China's high-end formulations. Several other complex injectable products are also about to be launched.
Nearly 100 Million Pre-A Round FinancingOn August 11, focusing onDevelopment of Innovative Small Molecule Drugs Targeting RNAOfLibo BiotechAnnouncement CompletedNearly 100 Million Pre-A Round FinancingThis round of financing was jointly led by Tasly Capital and Panlin Capital, with follow-up investments from YuSheng Ventures, Zhejiang Province's "4+1" Biopharmaceuticals and High-End Medical Devices Industry Fund, and Chengxin Ventures. Haoyue Capital served as the exclusive financial advisor for this round of financing.Libo Biotech is currently rapidly advancing the development of a series of pipelines in the fields of central nervous system, cancer, and autoimmune diseases. With the support of this round of financing, Libo Biotech will accelerate the IND submission and clinical research of its leading pipelines, and continue to expand its layout in the field of small molecules targeting RNA, striving to transform this cutting-edge technology into clinical breakthroughs.Libo Biotech was founded in September 2022 and received angel round investment from Innovation Works and Sequoia China Seed Fund in November of the same year. The company boasts an experienced and complementary founding team. Scientific founder Professor Yaoqi Zhou has been deeply engaged in the field of structural computation for nearly 30 years and is an international leader in RNA structure prediction, having developed a series of groundbreaking works including the MARS database, the RNA-MSM language model, the Spot-RNA secondary structure prediction method, and the BRiQ-RNA tertiary structure prediction method. The company's founder and CEO, Dr. Jian Zhan, has long been involved in the discovery, detection, and prediction of RNA tertiary structures and is a core inventor of "dry-wet closed loop" RNA stable tertiary structure discovery methods such as CODA and Mobi-Seq. Another founder, Dr. Chao Fang, has extensive experience in small molecule drug development, with over eight years of industrial experience in targeting RNA small molecules.Tens of Millions of Angel Round FinancingOn August 18, Yixuan Biotech (Shanghai) Co., Ltd. ("Yixuan Biotech" or "the Company") completed an angel round of financing worth tens of millions of yuan, jointly led by Fir Capital and Cold Spring Capital along with the Zhangjiang Sci-Tech Investment Ecosystem Fund. The Zhangjiang Life Health Industry Incubation Angel Fund ("Zhangke He Miao Fund") also participated in the investment.The funds raised in this round will accelerate the development of globally leading pan-nucleic acid drugs., focusing on breakthrough therapies for chronic and age-related diseases, and injecting strong momentum into the company's continuous innovation and global development in the future.
YiXuan Biotech was established in March 2025 in Zhangjiang Pharm Valley by a group of top industry experts, gathering an experienced international R&D team. The company focuses on the research and development of novel nucleic acid drugs, and with its proprietary precision delivery technology, has successfully overcome the limitations of traditional drug treatments, providing revolutionary therapeutic solutions for chronic and age-related diseases.The innovative drugs developed by Yixuan Bio overcome the high cost and safety challenges of emerging biotherapies such as cell and gene therapies, significantly improving drug accessibility. Its core technology platform not only demonstrates strong drug development potential but also establishes a technical barrier through global patent protection, laying a solid foundation for the widespread adoption of efficient and cost-effective treatment solutions.Tens of Millions of Market-Oriented FinancingOn August 19, Yinguan Biotech announced a phased progress in its market-oriented financing, securing tens of millions of yuan in market-driven funding from Hainan Kuncheng Wanxi Management Partnership (hereinafter referred to as "Kuncheng Wanxi"). This collaboration aims to integrate the advantageous resources of both parties to jointly advance the clinical progress of Yinguan Biotech's stem cell innovative drugs and international commercial cooperation.
Yinguan Biotech's strategic investor introduced this time, Kuncheng Wanxi, focuses on the biopharmaceutical industry and overseas resource integration. Cai Zhuofeng, Chief Investment Officer of Kuncheng Wanxi, emphasized that Yinguan Biotech is a representative cell industry chain enterprise, and its combination of leading technology, research, production, and commercialization capabilities is the core attraction for investment. He expressed hope that this cooperation would boost Yinguan Biotech’s rapid development and empower in-depth international collaboration.Yinguan Biotech, established in 2013, is a national high-tech enterprise specializing in the field of cell and gene therapy. It focuses on the research, development, and transformation of innovative cell drugs, exosome therapies, and drug-loading technologies. The company has built one exhibition hall, one library, and three platforms, strategically deploying six major industrial sectors: drug R&D, cell storage, cell CDMO, cell medical aesthetics, health management, and Yinguan Education. It continuously expands the application boundaries of biotechnology with the aim of creating a complete closed-loop cell industry chain.The company has established a dual-track industrialization model of "Innovative Drug IND + Record-filing Therapy IIT" to achieve strategic synergy in the breadth of indication coverage and the depth of R&D. It has laid out more than ten R&D pipelines, among which the stem cell platform leads South China in the number of IND acceptances for four stem cell drugs. The exosome platform's first exosome-conjugated small nucleic acid drug has completed PCC screening. The gene engineering platform collaborates with MIT technology to explore cross-platform technology integration.Tens of Millions of Dollars in Seed FundingOn August 20, Weicheng Pharmaceutical Co., Ltd. announced the completion of a multi-million-dollar seed funding round led by Apricot Capital and participated by Qiming Venture Partners.The funds from this round of financing will be mainly used for the development of the preclinical liver-targeted small nucleic acid platform and pipeline.In recent years, small nucleic acid drugs have developed rapidly, showing broad prospects in the field of disease treatment. Currently, all siRNA drugs in the commercialization stage are liver-targeted products, and there is still a significant unmet need and room for expansion in non-liver targeting. Compared with the mature GalNac delivery method for liver targeting, non-liver targeted delivery still faces considerable challenges in terms of receptor selection and ligand conjugation, absorption efficiency in target tissues, and safety. Relevant chemical modification methods are still undergoing continuous iteration and optimization.Voyager Therapeutics was founded in 2025, based on its proprietary extrahepatic delivery technology platform. The company focuses on the targeted delivery of small nucleic acid drugs to non-liver tissues, aiming to overcome the technical bottleneck that has traditionally limited small nucleic acid drugs to liver-targeted delivery, in order to meet unmet medical needs. The company’s international core team members have years of research and development experience in the field of small nucleic acids. They have led or been deeply involved in the development of multiple extrahepatic targeted nucleic acid drug pipelines, with practical experience in developing both extrahepatic antisense oligonucleotides (ASO) and siRNA pipelines.Nearly 100 Million Pre-A+ Financing RoundOn August 29, Shenzhen MagicRNA Biotechnology Co., Ltd. (hereinafter referred to as "MagicRNA") announced the completion of a nearly RMB 100 million Pre-A+ round of financing. This round of financing was led by IDG Capital, with participation from Hillhouse Ventures and YuanBio Venture Capital, while existing shareholder Hengye Capital continued to increase its investment. Chenglin Capital served as the financial advisor for this round. The proceeds will be used for the IND application and IIT clinical research of the core product HN2301.Hongxin Biotech was founded in December 2021 and is aFocused on the research and development of nucleic acid drug delivery and therapeutic mRNA innovative drugs, committed to innovation and breakthroughs in nucleic acid drug delivery technology. The company has developed a leading ionizable amino lipid library in China, and its core lipid (ILB3132) has been commercialized.To address the industry bottleneck of "mRNA extrahepatic and non-APC targeted delivery," Hongxin Biotech successfully established the Engineered Cell Targeted LNP Platform (EnC-LNP) in 2023, achieving internationally leading levels in engineering and targeted delivery efficiency. This platform provides strong support for the precise delivery of nucleic acid drugs. The In vivo CAR T pipeline developed based on the EnC-LNP platform completed the first dosing in an SLE patient in the first quarter of 2025, marking the world’s first clinical trial of cell-targeted LNPs in humans (First-in-human). Globally, this is also the first time that CAR T reprogramming and B-cell depletion have been achieved in humans, with good safety and preliminary clinical efficacy observed.Reference: Announcements from various companies
Mastering CAR-T Therapy, Stem Cell Therapy, Gene
Therapy,Comprehensive Information on Oncolytic Viruses and Nucleic Acid Drugs
